Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies

Recently, we constructed retroviral vector particles derived from spleen necrosis virus (SNV) that display a single-chain antibody (scA) on the viral surface. By transient transfection protocols, we showed that such particles are competent for infection and cell type specific. Efficient infection was dependent on the presence of wild-type envelope, although wild-type SNV was not infectious on target cells (T.-H. T. Chu and R. Dornburg, J. Virol. 69:2659-2663, 1995; T.-H. T. Chu, I. Martinez, W. C. Sheay, and R. Dornburg, Gene Ther. 1:292-299, 1994). In this study, stable packaging lines were constructed and detailed biological and biochemical studies were performed. Chimeric scA-envelope fusion proteins were expressed as efficiently as wild-type envelope and were stable over a period of at least 6 h. Only a fully functional wild-type envelope could act as a helper for efficient virus penetration. The ratio of wild-type envelope protein to chimeric envelope protein appears to determine the efficiency of infection. Virus titers of targeting vectors obtained from stable packaging lines were as high as 10(4) CFU/ml. A 25-fold concentration of vector virus stocks resulted in a 200-fold increase in virus titers (up to 10(6) CFU/ml). These data indicate that an inhibitor of infection was (at least partially) removed by the concentration protocol. Our data show that this technology has several variables for further improvements and, therefore, has the potential to become a powerful tool for cell-type-specific in vivo human gene therapy.

[1]  R. Dornburg,et al.  Mutational analysis of the envelope protein of spleen necrosis virus , 1996, Journal of virology.

[2]  R. Dornburg,et al.  Partial reconstitution of a replication-competent retrovirus in helper cells with partial overlaps between vector and helper cell genomes. , 1996, Human gene therapy.

[3]  L. Albritton,et al.  Analysis of the murine ecotropic leukemia virus receptor reveals a common biochemical determinant on diverse cell surface receptors that is essential to retrovirus entry , 1996, Journal of virology.

[4]  M. Zoppè,et al.  Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Dornburg,et al.  Mapping of receptor binding domains in the envelope protein of spleen necrosis virus , 1995, Journal of virology.

[6]  R. Dornburg.  Reticuloendotheliosis viruses and derived vectors. , 1995, Gene therapy.

[7]  R. Dornburg,et al.  Improved retroviral packaging lines derived from spleen necrosis virus. , 1995, Virology.

[8]  R. Dornburg,et al.  Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer , 1995, Journal of virology.

[9]  R. Dornburg,et al.  Highly efficient eukaryotic gene expression vectors for peptide secretion. , 1995, BioTechniques.

[10]  Y. Kan,et al.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. , 1994, Science.

[11]  R. Dornburg,et al.  Cell targeting with retroviral vector particles containing antibody-envelope fusion proteins. , 1994, Gene therapy.

[12]  K. Jeang,et al.  Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention. , 1994, Human gene therapy.

[13]  R. Dornburg,et al.  Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. , 1993, BioTechniques.

[14]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[15]  G. Winter,et al.  Retroviral vectors displaying functional antibody fragments. , 1993, Nucleic acids research.

[16]  S. Carillo,et al.  The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. , 1992, The Journal of general virology.

[17]  T. Mikawa,et al.  In vivo analysis of a new lacZ retrovirus vector suitable for cell lineage marking in avian and other species. , 1991, Experimental cell research.

[18]  H. Varmus,et al.  Efficient incorporation of human CD4 protein into avian leukosis virus particles. , 1990, Science.

[19]  L. Lee,et al.  Monoclonal antibodies against avian reticuloendotheliosis virus: identification of strain-specific and strain-common epitopes. , 1986, Journal of immunology.

[20]  H. Temin,et al.  Different localization of the product of the v-rel oncogene in chicken fibroblasts and spleen cells correlates with transformation by REV-T , 1986, Cell.

[21]  M. Nishizawa,et al.  New procedure for DNA transfection with polycation and dimethyl sulfoxide , 1984, Molecular and cellular biology.

[22]  M Vapalahti,et al.  [Human gene therapy]. , 1996, Duodecim; laaketieteellinen aikakauskirja.

[23]  E. Poeschla,et al.  Progress towards gene therapy for HIV infection. , 1994, Gene therapy.

[24]  C. Caskey,et al.  Gene therapy of the immune system. , 1993, Annual review of immunology.

[25]  R. Swanstrom,et al.  Retrovirus envelope glycoproteins. , 1990, Current topics in microbiology and immunology.